95 related articles for article (PubMed ID: 22704893)
1. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
Blayney JK; Ceresoli GL; Castagneto B; O'Brien ME; Hasan B; Sylvester R; Rudd R; Steele J; Busacca S; Porta C; Mutti L; O'Byrne KJ; Scullin P; Gaafar R; Baas P; Van Meerbeeck J; Fennell DA
Eur J Cancer; 2012 Nov; 48(16):2983-92. PubMed ID: 22704893
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
4. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
5. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
[TBL] [Abstract][Full Text] [Related]
6. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
7. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A
Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487
[TBL] [Abstract][Full Text] [Related]
8. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
[TBL] [Abstract][Full Text] [Related]
9. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
11. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
[TBL] [Abstract][Full Text] [Related]
12. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
[TBL] [Abstract][Full Text] [Related]
15. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.
Xia H; Karasawa K; Hanyu N; Chang TC; Okamoto M; Kiguchi Y; Kawakami M; Itazawa T
Int J Hyperthermia; 2006 Nov; 22(7):613-21. PubMed ID: 17079218
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
19. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
20. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
